What is Stifel Canada's Estimate for TSE:GUD Q1 Earnings?

Knight Therapeutics Inc. (TSE:GUD - Free Report) - Equities research analysts at Stifel Canada issued their Q1 2025 earnings per share estimates for shares of Knight Therapeutics in a report issued on Monday, March 24th. Stifel Canada analyst J. Keywood forecasts that the company will post earnings of $0.03 per share for the quarter. The consensus estimate for Knight Therapeutics' current full-year earnings is $0.10 per share. Stifel Canada also issued estimates for Knight Therapeutics' Q3 2025 earnings at $0.06 EPS, Q4 2025 earnings at $0.04 EPS and FY2026 earnings at $0.21 EPS.

A number of other equities analysts have also weighed in on GUD. Stifel Nicolaus upped their target price on shares of Knight Therapeutics from C$6.25 to C$7.45 and gave the stock a "buy" rating in a research note on Tuesday, March 25th. Canaccord Genuity Group lowered shares of Knight Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, March 21st. Finally, Research Capitl upgraded Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of C$7.48.

Knight Therapeutics Stock Up 0.5 %

Shares of Knight Therapeutics stock traded up C$0.03 on Thursday, hitting C$6.12. The company had a trading volume of 52,707 shares, compared to its average volume of 70,400. The stock has a 50-day moving average of C$5.74 and a 200-day moving average of C$5.60. The company has a debt-to-equity ratio of 7.52, a current ratio of 3.36 and a quick ratio of 1.79. Knight Therapeutics has a twelve month low of C$5.09 and a twelve month high of C$6.45. The firm has a market capitalization of C$619.04 million, a P/E ratio of -20.43, a P/E/G ratio of -1,013.50 and a beta of 0.50.

Remove Ads

Insider Activity at Knight Therapeutics

In other Knight Therapeutics news, insider Sime Armoyan purchased 17,600 shares of the business's stock in a transaction on Tuesday, March 4th. The stock was acquired at an average price of C$5.48 per share, with a total value of C$96,488.48. In the last ninety days, insiders sold 3,143,300 shares of company stock worth $19,733,740. Insiders own 45.62% of the company's stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.